Williamstown, MA -- (SBWIRE) -- 02/14/2012 -- Despite some commentators predicting a muted or near nonexistent market for advanced biosimilars, many companies - and some surprising names - are positioning themselves for market entry.
Examining the market for companies
The need for a settled market environment is essential if the growing numbers of biologic products losing patent protection in the next 5-10 years is to be exploited. However, progress is painfully slow and critical issues driving the market dynamic include:
Industry investment: a sign of confidence?
This report provides a detailed analysis of 50 companies active in the biosimilars field, many of which have declared their interest in 2011. The move may reflect a growing confidence that as regulatory provision for biosimilars increases, and as the pipeline of prospective products matures, then the prospect of actually being able to launch products grows more realistic.
The US continues to disappoint; Europe forges ahead
Despite President Obama's health reform bill being passed in 2010, very little has happened. And the FDA's cautious approach suggests little will happen in the immediate future. The much anticipated Guidance, expected in 2011 has failed to appear, and in May 2011 FDA published details for User Fees - a scheme that will not come into effect(assuming it is passed by Congress) until 2013. Given that an untried regulatory system will not operate at the fastest speed then prospects of a US market for advanced biosimilars seem remote before 2015. In contrast, European regulators are revising their widely-adopted regulations in the light of experience, with a view to issuing revisions and guidance in 2012.
View Full Report Details and Table of Contents
Developing markets may offer a profitable alternative
Developing markets with rising disposable incomes may present the medium-term prospect for biosimilars, since they combine a large target population with reduced operating costs. Many countries are following the EU model of regulation. Markets such as India and China have plenty of home-grown production capacity. Some companies have sought to turn this capacity to their advantage, and have signed deals with Chinese/Indian producers for the development of products to be sold around the world.
This report provides a comprehensive insight to the market environment,current and future products and the companies involved.
A complete examination of the regulatory situation in the US, Europe and emerging markets
Detailed assessment of current biosimilar products and developers with market share by product
- Human Insulin
- Interferon (alfa & beta)
Identification and analysis of likely second wave of advanced biologics to come to the market
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment
- Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars
- Competing For Share Of Global Pharmaceutical Industry Spend In 2010-2011: Supplier Marketing & Sales Strategies & Industry Outlook
- What The Global Pharmaceutical Industry Is Planning In 2010-2011: Procurement, Investment & Industry Trends Outlook
- Biological Therapies for Cancer: Technologies and Global Markets
- Global Biosimilars: Identifying 2nd Generation Opportunities
- Prostate Cancer - Brazil, China, India and Russia (BRIC) Drug Forecasts and Treatment Analysis to 2020
- Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies
- Biosimilars (2009 - 2014)
- What The Global Upstream Oil & Gas Industry Is Planning In 2010-2011: Procurement, Investment & Industry Trends Outlook